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INTRODUCTION 
 
 
   WHAT IS A PRION-LIKE PROTEIN? 
   
LIQUID-LIQUID PHASE SEPARATION 
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Figure 1: Folding funnel hypothesis [1]. 
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Figure 2: TDP-43 and FUS sequences  representation [2]. 
Figure 3: Liquid-liquid phase separation 
process [3]. 
Proteins are molecules implied in 
a myriad of tasks in the cell. To 
perform biological functions, 
proteins need to fold into defined 
three-dimensional structures. 
Mistakes in this complex process 
produce unfolded states, 
ultimately leading to the 
formation of stable aggregates. 
 
The role played by intrinsically 
disordered proteins in cell 
processes is receiving increasing 
attention. These proteins 
promote phase separation states 
in cytoplasm and punctual 
mutations in their sequences are 
behind neurodegenerative 
disorders. 
NEUROPATHOLOGY OF PRION-LIKE PROTEINS 
 
ABERRANT PHASE TRANSITION 
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Mistakes in phase separation equilibrium 
produce an aberrant transition to a fibrous 
and pathological state. 
What is 
needed for 
a liquid 
phase 
separation? 
 Interactions among Low 
Complexity Domains 
 
 A defined protein 
concentration that does 
not compromise 
dynamism 
Which is the 
main source 
promoting 
an aberrant 
phase 
transition? 
Mutations in 
Prion-like proteins 
 
 High 
concentration of 
Prion-like proteins 
inside  phase 
separation 
Punctual mutations in Low 
Complexity Domains promote an 
aberrant phase transition 
Figure 5: The aberrant phase transition is clear 
in G156E FUS sample at 8h [5]. 
Low Complexity Domains of 
Prion-Like proteins are 
essential to promote phase 
transition 
Low Complexity Domain  of TIA1 
mediates aggregation reactions in  
the presence of b-isox compound 
Figure 4: Different recombinant variants of TIA1-GFP 
localize in different fractions depending on the presence 
of b-isox [4]. 
Figure 6: The alteration of liquid-like state  equilibrium leads 
to pathological conformations [6]. 
Mutations in Prion-like proteins are involved in 
the onset of neurodegenerative disorders. 
 Punctual mutations in FUS protein are related 
with the onset of ALS 
FUS-R521C 
mutant 
decreases 
dendrite 
growth 
Figure 7: Effects of FUS-R521C in dendritic 
arborization are clear in cortical neurons [7]. 
Failure in FUS-dependent 
DNA repair causes 
neurodegeneration 
Figure 8: Mechanisms of FUS and HDAC1 in 
DNA repair [7]. 
CONCLUSION 
 
Prion-Like proteins are a group of proteins sharing long disordered 
domains rich in Gly, Tyr and polar amino acids, known as Low 
Complexity Domains (LC domain). Most of these polypeptides are 
DNA or RNA binding proteins and they are important components of 
non-membrane functional structures. 
Fused in 
Sarcoma 
(FUS) protein 
as an 
example of 
Prion-Like 
protein 
 Predominantly 
nuclear protein 
 
 Involved in RNA 
homeostasis 
 
Related with 
Amyotrophic 
Lateral Sclerosis 
(ALS) 
 
In contrast to what is usually assumed, the neurotoxic mechanism 
behind the aberrant phase transition of prion-like proteins is not 
caused by the intrinsic toxicity of the amyloid-like aggregates, but 
rather results from the role of RNA-binding proteins in transcriptional 
and DNA repair processes. Amyloid-like deposits inhibit the correct 
function of RNA-binding proteins, decreasing cell fitness and 
viability.  
This  novel mechanism will change the way we look at 
neurodegenerative disorders, likely opening novel therapeutic 
opportunities. 
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